ClinicalTrials.gg
RecruitingNCT06093438Updated Mar 11, 2025

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

A Phase 1/2 interventional study of Toripalimab in Cervical Cancer, Induction Chemotherapy and Immunotherapy, sponsored by Tianjin Medical University Cancer Institute and Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing toripalimab in Uterine Cervical Neoplasms — 4 open to participants now, 5 under way, none of them phase 3. toripalimab · Uterine Cervical Neoplasms.

Planned enrollment
8th of 10
20 · median 33
Started
2023
the only one that year
Phase 1/2
2 of 10
1 open now
Registered
6th of 10
by date
Lead sponsor
2 of 10
Tianjin Medical University Cancer Institute and Hospital

Among the 10 studies testing toripalimab in Uterine Cervical Neoplasms, this one is the 8th largest by planned enrollment, is the only one that started in 2023, is one of 2 in phase 1/2, and was the 6th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 10 studies testing toripalimab in Uterine Cervical Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing toripalimab in Uterine Cervical Neoplasms, or all of them as a file.
02

Study summary

To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.

Read the detailed description

For locally advanced cervical cancer patients undergoing definitive chemoradiotherapy, distant metastasis has become a major concern. In this study, investigators selected a subgroup of patients with theoretically higher risk of distant metastasis and intensified their systematic treatment by incorporating PD-L1 inhibitors into neoadjuvant chemotherapy, in order to reduce their risk of distant metastasis and achieve good disease-free survival.

03

Conditions studied

  • Cervical Cancer
  • Induction Chemotherapy
  • Immunotherapy

Keywords

  • cervical cancer
  • immunotherapy
  • neoadjuvant chemotherapy
  • chemoradiation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Untreated locally advanced cervical cancer patients with clear pathological diagnosis
  2. 2019 FIGO stage IIIB-IVA. For patients with stage IIIC disease, the short diameter of their lymph nodes should ≥1.5cm
  3. (ECOG) Performance Status 0-1
  4. > 6 months
  5. Able to tolerate concurrent chemoradiotherapy assessed by researches
  6. No obvious active bleeding;
  7. Adequate hematological, renal and hepatic functions:
  8. No concomitant
  9. Female subjects of should have a negative pregnancy test and must take effective and reliable measures during the clinical trial period;
  10. Voluntarily-signed .

Exclusion criteria

Exclusion Criteria:

  1. Concomitant other ;
  2. Patients with or recurrent disease;
  3. Patients received any form of treatment before enrollment;
  4. Severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections;
  5. Impaired hematological, renal or hepatic functions:

    1. \< 9.0 g/dl
    2. Neutrophils \< 2000 cells/μl; Leukocytes \< 4 × 109/L
    3. > 100 × 109/L
    4. Serum /AST > 2.5×UNL
    5. Serum Total > 1.5× UNL

    g. Serum urea nitrogen (BUN) > 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr) > 1.5 × upper normal limit (UNL)

  6. Patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease;
  7. Patients with uncontrolled mental diseases;
  8. Pregnant or lactating woman;
  9. Participating in other clinical trials;
  10. Anyone considered not suitable for enrollment by principal investigator;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Induction immunotherapy and chemotherapy

    Patients enrolled in this arm would receive neoadjuvant immunotherapy and chemotherapy before definitive chemoradiation

    Drug: Toripalimab

Interventions

  • Patients enrolled in this arm would receive three cycles of induction treatment before receiving definitive chemoradiotherapy. The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d. Patients would receive pelvic MRI to evaluate the regression status of tumor after three cycles of induction treatment. Patients with satisfying tumor regression would receive definitive chemoradiotherapy afterwards. During chemoradiotherapy, patients would receive weekly cisplatin (40mg/m2) and 240mg toripalimab every three weeks. After chemoradiotherapy, patients would receive another three cycles of consolidated treatment (regimen identical to induction treatment).

06

What researchers measure

Primary outcomes

  1. Overall response rate

    The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1

    Time frame: 1 year

  2. Volume changes of core radiation targets and irradiated normal tissues after induction treatment

    Volume change of PTV, PGTVnd, Bladder V45, V50, Dmax, Dmean, Rectum V45, V50, Dmax, Dmean, Bowel bag V45, V50

    Time frame: 5-year

Secondary outcomes

  1. Progression-free survival

    Time from diagnosis of disease to disease progression or death due to any cause

    Time frame: 1-year, 2-year

  2. Distant metastasis-free survival

    Time from diagnosis to distant metastasis or death due to any cause

    Time frame: 1-year, 2-year

  3. Incidence of treatment-related side effects

    Incidence of treatment-related side effects (i.e., radiation-related proctitis, cystitis, ,vaginitis, etc.)

    Time frame: 5-year

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2025, 24 months after the start.

Of 81 phase 1/2 interventional studies under Uterine Cervical Neoplasms, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 75. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 23, 2023
StartActual
Nov 1, 2023
Primary completionEst.
Nov 1, 2025
CompletionEst.
Jul 1, 2026
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06093438
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Nov 1, 2023
Primary completion
Nov 1, 2025 (estimated)
Completion
Jul 1, 2026 (estimated)
Last update
Mar 11, 2025

Study contacts

Yuanjie Cao
Contact
cyjro325@gmail.com
+86-18522123151
Chen Li
Contact
lichen.radonco@tmu.edu.cn
+86-15510932601
Jie Chen
principal investigator · Tianjin Medical University Cancer Institute and Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Toripalimab

Start the discussion